Sun Pharma Shares Climb Over 4% After Announcing $11.75 Billion Organon Buyout

By Kotak News Desk
|
27 Apr 2026 at 11:03 AM IST
|
Market News
|
4 minutes read

Stay updated with the latest stock market developments and trends.

You can set Kotak Neo as a preferred source to receive regular market updates.

Summary

Shares of Sun Pharma jumped by more than 4% post news of the acquisition of Organon & Co. in a transaction of nearly $12 billion. It is anticipated that the move will bolster the company's global footprint.

Shares of Sun Pharmaceutical Industries moved higher on Monday after the company announced plans to acquire Organon & Co. in a deal valued at $11.75 billion.

The deal marks Sun Pharma’s entry into biosimilars. It places the company among the top 10 global players.

Sun Pharma shares rose more than 4% in early trade as investors reacted to one of the biggest overseas acquisitions by an Indian drugmaker. At 10:49 AM, it traded over 7% higher at ₹1,741.50.

Details Of The deal

Sun Pharma said it has signed a definitive agreement to purchase all outstanding shares of Organon for $14 per share in cash. The total enterprise value of the transaction stands at around $11.75 billion.

The transaction is anticipated to be completed around early 2027, subject to obtaining regulatory approvals and fulfilling other usual conditions.

About Organon & Co.

Organon & Co. is a company with a very extensive global footprint, carrying out its activities in more than 140 countries. The company's product range comprises women's health products, biosimilars, and well-known drugs.

The business also has multiple manufacturing facilities and an established commercial network in key global markets.

For Sun Pharma, the transaction offers entry into new segments while widening its international footprint.

What Sun Pharma Gains

After the merger, the combined company is expected to have annual revenue of over $12 billion. Sun Pharma said the acquisition will strengthen its innovative medicines business and improve scale in branded generics.

The deal may also help the company build a stronger presence in women’s healthcare and biosimilars, areas where Organon already has a meaningful presence.

The executives of the company described the deal as a strategic move with the potential to develop a larger and more varied pharmaceutical platform. Besides this, they drew attention to potential synergies tied to product launches, expanded distribution, and increased operational scale.

Also Read - Stock Market Update 27 April 2026: Sensex Gains Over 400 Pts; Nifty 50 Above 24,000

Investor Takeaway

Sun Pharma shares had seen pressure in recent weeks amid speculation around a large acquisition. Monday’s rise suggests investors welcomed greater clarity after the formal announcement.

The next key milestones will be regulatory approvals, financing structure, and how the company plans to integrate the overseas business after closing.

Sources:

The Economic Times

The Financial Express

This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.

About the Author